Incyte (NASDAQ:INCY) Receives “Neutral” Rating from UBS Group
UBS Group restated their neutral rating on shares of Incyte (NASDAQ:INCY – Free Report) in a research note published on Tuesday,Benzinga reports. UBS Group currently has a $61.00 price objective on the biopharmaceutical company’s stock. A number of other brokerages also recently weighed in on INCY. Wall Street Zen raised shares of Incyte from a […]
UBS Group restated their neutral rating on shares of Incyte (NASDAQ:INCY – Free Report) in a research note published on Tuesday,Benzinga reports. UBS Group currently has a $61.00 price objective on the biopharmaceutical company’s stock. A number of other brokerages also recently weighed in on INCY. Wall Street Zen raised shares of Incyte from a […]
